You just read:

Landmark Phase 3 VOYAGER PAD Study of XARELTO® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization

News provided by

Janssen Pharmaceutical Companies of Johnson & Johnson

Mar 28, 2020, 10:13 ET